A phase 2 trial evaluated the safety and efficacy of quizartinib in patients with relapsed/refractory acute myeloid leukemia (AML), compared with salvage chemotherapy.
David Bai
Advertisement
Articles by David Bai
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
3
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5